SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-007941
Filing Date
2024-01-26
Accepted
2024-01-26 16:15:19
Documents
13
Period of Report
2024-01-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sabs-20240126.htm   iXBRL 8-K 46398
2 EX-1.1 sabs-ex1_1.htm EX-1.1 356768
3 EX-5.1 sabs-ex5_1.htm EX-5.1 13644
4 GRAPHIC img84541401_0.jpg GRAPHIC 6808
  Complete submission text file 0000950170-24-007941.txt   639823

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sabs-20240126.xsd EX-101.SCH 45415
7 EXTRACTED XBRL INSTANCE DOCUMENT sabs-20240126_htm.xml XML 6415
Mailing Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104
Business Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104 605-679-6980
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

IRS No.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39871 | Film No.: 24567926
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)